Galaxy Biomedical Investment Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 1,135.84 million compared to CNY 789.8 million a year ago. Revenue was CNY 1,135.84 million compared to CNY 789.8 million a year ago.

Net loss was CNY 48.8 million compared to CNY 157.7 million a year ago. Basic loss per share from continuing operations was CNY 0.0444 compared to CNY 0.1434 a year ago. Diluted loss per share from continuing operations was CNY 0.0444 compared to CNY 0.1434 a year ago.